NYSE:PFE

Pfizer Inc (PFE)

24.98
-0.03 (0.12%)
as of Aug 3, 2026, 3:02:42 pm Market Open.
581 watching
0
Investor Insights
star iconAug 3, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc (PFE) is currently navigating a challenging landscape post-COVID, grappling with the loss of patent exclusivity on several of its major drugs. Analysts express a mix of cautious optimism and concern about the company's ability to develop new blockbuster drugs to replenish its pipeline. The consensus highlights a generous dividend yield, typically around 6-8%, which appeals to income-focused investors. However, there's significant uncertainty regarding growth, with many experts pointing to the company's recently acquired drugs and strategic focus on obesity and oncology as potential avenues for future success. Overall, while the stock is deemed undervalued based on its low price-to-earnings ratio, the lack of immediate catalysts for growth and dependency on dividends reflect a complex investment landscape.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
TOP PICK
47% positive differential. The most mispriced in the Dow Jones. bonus of 5% dividend yield. They are in around $26.63.
TOP PICK
(A Top Pick July 21/06. Up 14.5%.) 5% yield. His model price is $48.51, a 52% positive differential. The cheapest stock in the Dow Jones.
COMMENT
Is preforming quite well without a lot of fanfare. Thinks it is going to trade to a discount, would rather go to a Sheering or Abbot.
TOP PICK
Hasn't moved but has the most value of similar stocks. Massively mispriced.
COMMENT
Blue chip. Nice dividend. Don't expect too much excitement.
PAST TOP PICK
(A Top Pick May 9/06. Up 4.2%.) Yield gave him another 4%. Sold their consumers products division for $19 billion so have a huge amount of cash on the books. Can't see a lot of downside here.
DON'T BUY
Has value characteristics which is positive, but he can't get comfortable with their largest drug Lipidor going off patent in 2011. Does not all they'll make up for this.
BUY
His value drug play. Growth drug play is Teva Pharmaceutical (TEVA-Q). Pharmaceuticals got the wind kicked out of them a couple of years ago and are now showing some rebound. Very nice yield. Huge cash hoard and are buying back stock and probably will increase dividends again.
BUY ON WEAKNESS
Looks like it is in the process of breaking the downtrend. That was established with the recent higher lows. If you own, he would Hold.
TOP PICK
(A Top Pick May 10/06. Up 5.3%.) One of the cheapest stocks on the S&P500. His model price is $40.47 giving it a 55% positive differential. Any positive catalyst will help the stock price. Dividends are almost 5%.
BUY
The drug stocks in the US have been beat up. The problems they had have gotten somewhat better. Increased their dividend and are investing in more R&D. Buying back shares. Low multiple.
DON'T BUY
Doesn't like many of the big pharmaceuticals. Has a great deal of revenue at risk with Lipitor coming off patent and they don't have a lot to replace it.
PAST TOP PICK
(A Top Pick Dec 5/06. Up to .3%.) Still has lots of upside and it has a good yield. Have a lot of cash.
PAST TOP PICK
(A Top Pick Dec 21/06. Down 2.5%.) Sold their consumer business. There is so much value there. New management is cutting costs. 4.7% dividend. Still likes.
BUY
Pays a nice dividend. Have tons of cash through their normal cash generation as well as selling their consumers product division. Using some of it to increase dividends and some to buy back shares. 13 X earnings.
Showing 571 to 585 of 885 entries